An Israeli medical device startup focusing on cardiovascular medical devices announced the securing of $6 million in Series A1 investment round from private healthcare investors. Filterlex Medical can now accelerate implementation of the startup’s CAPTIS® clinical program evaluating the next-generation, full-body embolic protection device designed to reduce the risk of stroke and other complications during left-heart procedures.
The company recently issued a press release announcing its funding and intentions to develop the CAPTIS device, designed to deal with the risks associated with catheter-based procedures. One example provided, Transcatheter Aortic Valve Replacement (TAVR), involves the common release of embolic particles into the blood flow which can trigger neurological deficiencies from cognitive impairment to debilitating stroke.
The Investigational Product
In a recent first-in-human study the CAPTIS device was easily and intuitively deployed and retrieved reports the study’s startup sponsor. They point out the device was “securely positioned in the aorta, protecting its surface, while facilitating a seamless TAVR procedure...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).